Retatrutide vs MK-677
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and MK-677 (Ibutamoren). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | MK-677 Ibutamoren, Nutrobal |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | Phase 2 |
| Category | Weight Loss | Growth Hormone |
| Primary Use | Obesity and weight management | Growth hormone optimization and muscle growth |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $50 - $100/mo |
| Administration | Subcutaneous injection | Oral |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 10-25mg daily |
| Frequency | Weekly | Daily |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Phase 3 | Phase 2 |
Key Differences
- 1Retatrutide has clinical weight loss data (28.7%), while MK-677 is not primarily indicated for weight loss.
- 2MK-677 is generally more affordable ($50 - $100/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 3Retatrutide is administered via subcutaneous injection, while MK-677 uses oral.
- 4Retatrutide is dosed weekly, while MK-677 is daily.
- 5Retatrutide has high-quality evidence, while MK-677 has moderate-quality evidence.
- 6They belong to different categories: Retatrutide (Weight Loss) vs MK-677 (Growth Hormone).
Which Is Better For...
MK-677
More budget-friendly option with lower monthly costs
Retatrutide
More convenient dosing schedule (weekly)
MK-677
Fewer commonly reported side effects
Retatrutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| MK-677 | $50 - $100/mo | Phase 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. MK-677 is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideMK-677 (Ibutamoren) is an orally-active growth hormone secretagogue that mimics the action of ghrelin. Unlike peptide injections, it is taken orally and has a long half-life allowing once-daily dosing...
View Full MK-677 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and MK-677 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.